MCID: BRD004
MIFTS: 45

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD10 33 F60.3
ICD9CM 35 301.83
MeSH 42 D001883
NCIt 47 C92633
SNOMED-CT 64 192488005 20010003
UMLS 69 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to personality disorder and heroin dependence. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are cAMP signaling pathway and Calcium signaling pathway. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 72 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder, is a... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
id Related Disease Score Top Affiliating Genes
1 personality disorder 30.1 BDNF COMT HTR1A HTR2A HTR2C MAOA
2 heroin dependence 29.9 BDNF HTR1B MAOA SLC6A4
3 schizophrenia 27.4 BDNF COMT HTR1A HTR1B HTR2A HTR2C
4 obsessive-compulsive personality disorder 23.4 AVPR1A BDNF COMT FKBP5 HTR1A HTR1B
5 sexual sadism 10.8
6 impulse control disorder 10.8
7 chitty hall webb syndrome 10.6 COMT TPH1
8 conjunctival pigmentation 10.6 MAOA SLC6A4
9 ring chromosome 14 syndrome 10.6 COMT MAOA
10 ornithosis 10.5 MAOA SLC6A4
11 splenic abscess 10.5 HTR2A SLC6A4
12 paranoid personality disorder 10.5 HTR1A HTR2A
13 teebi kaurah syndrome 10.5 COMT HTR2A
14 hyperthyroxinemia 10.5 HTR2A SLC6A4
15 polyneuropathy 10.5 HTR1A HTR2A
16 hodgkin's granuloma 10.5 HTR1A HTR2A
17 amyloidosis, finnish type 10.4 COMT MAOA
18 hemorrhagic cystitis 10.4 COMT MAOA SLC6A4
19 pervasive developmental disorder 10.4 BDNF COMT SLC6A4
20 anosognosia 10.4 COMT HTR1A SLC6A4
21 tongue disease 10.4 COMT MAOA SLC6A4
22 luxation of globe 10.3 HTR1A SLC6A4
23 tinea pedis 10.3 HTR1A MAOA SLC6A4
24 angiokeratoma of mibelli 10.3 HTR1A MAOA SLC6A4
25 neurogenic bladder 10.3 HTR2A MAOA SLC6A4
26 pyromania 10.3 HTR2A MAOA SLC6A4
27 bipolar disorder 10.3
28 allergic hypersensitivity disease 10.3 HTR1A HTR2A
29 hepatic angiomyolipoma 10.2 BDNF HTR2A SLC6A4
30 transsexualism 10.2 BDNF HTR1A
31 ulcerative colitis 10.2 BDNF COMT
32 bulimia nervosa 10.2
33 carotid stenosis 10.1 COMT MAOA SLC6A4 TPH1
34 vascular cancer 10.1 HTR1A HTR2A
35 hepatopulmonary syndrome 10.1 COMT HTR2A TPH1
36 attention deficit-hyperactivity disorder 10.1
37 substance dependence 10.1
38 uterus intravascular leiomyomatosis 10.1 COMT HTR1A MAOA SLC6A4
39 chromosome 11p13 deletion syndrome, distal 10.0 BDNF COMT HTR2A SLC6A4
40 mood disorder 10.0
41 alexithymia 10.0
42 somatoform disorder 10.0
43 eating disorder 10.0
44 antisocial personality disorder 10.0
45 myopathy, distal, with early respiratory failure, autosomal dominant 10.0 COMT TPH1
46 parkinsonism-dystonia, infantile 10.0 COMT HTR2A MAOA TPH1
47 bladder flat intraepithelial lesion 10.0 BDNF HTR1A HTR2A SLC6A4
48 acquired aneurysmal subarachnoid hemorrhage 10.0 HTR1A HTR2A MAOA SLC6A4
49 perinatal necrotizing enterocolitis 10.0 BDNF COMT HTR2C SLC6A4
50 multiple personality disorder 10.0

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety Disorder
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 AVPR1A BDNF COMT FKBP5 HTR1A HTR1B
2 cardiovascular system MP:0005385 9.92 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
3 homeostasis/metabolism MP:0005376 9.85 AVPR1A BDNF COMT FKBP5 HTR1A HTR2C
4 endocrine/exocrine gland MP:0005379 9.8 HTR2A NR3C1 SLC6A4 AVPR1A BDNF COMT
5 muscle MP:0005369 9.5 HTR1B HTR2A HTR2C NR3C1 SLC6A4 TPH1
6 nervous system MP:0003631 9.23 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
7 Antidepressive Agents Phase 4,Phase 2
8 Antidepressive Agents, Second-Generation Phase 4,Phase 2
9 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2
11
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
12 Serotonin Agents Phase 4,Phase 3,Phase 2
13 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
14 Antiparkinson Agents Phase 4,Phase 2
15 Autonomic Agents Phase 4,Phase 3,Phase 2
16 Cholinergic Agents Phase 4,Phase 2
17 Cholinergic Antagonists Phase 4,Phase 2
18 Muscarinic Antagonists Phase 4,Phase 2
19 Parasympatholytics Phase 4,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21 Antipsychotic Agents Phase 4,Phase 3,Phase 2
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
23 Dopamine Agents Phase 4,Phase 2
24 Dopamine Antagonists Phase 4,Phase 2
25 Serotonin Antagonists Phase 4,Phase 2
26 Tranquilizing Agents Phase 4,Phase 3,Phase 2
27 Anticonvulsants Phase 4,Phase 3
28 calcium channel blockers Phase 4
29 Calcium, Dietary Phase 4
30 Diuretics, Potassium Sparing Phase 4
31 Excitatory Amino Acid Antagonists Phase 4
32 Excitatory Amino Acids Phase 4
33 Sodium Channel Blockers Phase 4
34 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Omega 3 Fatty Acid Nutraceutical Phase 4
37
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
38
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
39
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2 16590-41-3 5360515
40
Ethanol Approved Phase 3,Phase 2 64-17-5 702
41 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
42 Antiemetics Phase 3
43 Gastrointestinal Agents Phase 3
44 Narcotic Antagonists Phase 3,Phase 2
45 Narcotics Phase 3,Phase 2
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents, Local Phase 3,Phase 2
48 Protective Agents Phase 3,Phase 2,Phase 1
49
Oxytocin Approved, Vet_approved Phase 2,Phase 1 50-56-6 439302 53477758
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 135)

id Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
10 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
11 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
12 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
13 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
14 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
15 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
16 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
17 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
18 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
19 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
20 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
21 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
22 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
23 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
24 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
25 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
26 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
27 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
28 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Recruiting NCT01212588 Phase 2 mifepristone;Placebo
29 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
30 Acetaminophen and Social Processes Active, not recruiting NCT02108990 Phase 2 Acetaminophen
31 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
32 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
33 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
34 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
35 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
36 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
37 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
38 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497
39 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
40 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 guanfacine (Tenex)
41 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634
42 CPT Group for DBT Clients With Co-Occurring Borderline Personality Disorder and PTSD Unknown status NCT02574429
43 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781
44 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708
45 DBT in Borderline Personality Disorder Unknown status NCT00252031
46 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 methylphenidate
47 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554 Escitalopram
48 Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder Unknown status NCT01683136
49 "The Effects of Oxytocin on Patients With Borderline Personality Disorder" Unknown status NCT01243658 Oxytocin
50 Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT) Unknown status NCT01904227

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

39
Brain, Amygdala, Bone, Testes, Ovary, Pituitary, Cortex

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 725)
id Title Authors Year
1
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
2
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
3
Face and gaze perception in borderline personality disorder: An electrical neuroimaging study. ( 28941875 )
2017
4
Borderline personality disorder and polycystic ovary syndrome: A review of the literature. ( 28891300 )
2017
5
Resting cardiac function in adolescent non-suicidal self-injury: The impact of borderline personality disorder symptoms and psychosocial functioning. ( 28039803 )
2017
6
Estimating the prevalence of borderline personality disorder in mothers involved in youth protection services. ( 28944592 )
2017
7
Helping mothers with the emotional dysregulation of borderline personality disorder and their infants in primary care settings. ( 28892598 )
2017
8
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. ( 28072039 )
2017
9
Efficacy of metacognitive training for patients with borderline personality disorder: Preliminary results. ( 28927866 )
2017
10
Determining if Borderline Personality Disorder and Bipolar Disorder Are Alternative Expressions of the Same Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. ( 28922592 )
2017
11
Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group. ( 28659980 )
2017
12
Associations of borderline personality disorder traits with stressful events and emotional reactivity in women with bulimia nervosa. ( 28691843 )
2017
13
The Relationship between Survival Sex and Borderline Personality Disorder Symptoms in a High Risk Female Population. ( 28885558 )
2017
14
Outcome Trajectories and Prognostic Factors for Suicide and Self-Harm Behaviors in Patients With Borderline Personality Disorder Following One Year of Outpatient Psychotherapy. ( 28910214 )
2017
15
Substance Misuse Is Associated With Increased Psychiatric Severity Among Treatment-Seeking Individuals With Borderline Personality Disorder. ( 28910215 )
2017
16
Subgroups of Adolescent Girls With Borderline Personality Disorder Symptoms. ( 28926303 )
2017
17
Change of Unresolved Attachment in Borderline Personality Disorder: RCT Study of Transference-Focused Psychotherapy. ( 28903103 )
2017
18
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
19
"Abandonment Psychotherapy" for Suicidal Patients with Borderline Personality Disorder: Long-Term Outcome. ( 28903102 )
2017
20
Interpersonal Threat Sensitivity in Borderline Personality Disorder: An Eye-Tracking Study. ( 28072041 )
2017
21
Clinical Characteristics of Comorbid Narcissistic Personality Disorder in Patients With Borderline Personality Disorder. ( 28758884 )
2017
22
Contrasting metacognitive, social cognitive and alexithymia profiles in adults with borderline personality disorder, schizophrenia and substance use disorder. ( 28826064 )
2017
23
Personality organization and its association with clinical and functional features in borderline personality disorder. ( 28923434 )
2017
24
Substance Use in Youth With Borderline Personality Disorder. ( 28926304 )
2017
25
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 28072044 )
2017
26
Pain Perception and Body Awareness Among Individuals With Borderline Personality Disorder. ( 28902571 )
2017
27
Comorbidity study of borderline personality disorder: applying association rule mining to the Taiwan national health insurance research database. ( 28077135 )
2017
28
Compelled to Risk: Does Sexual Compulsivity Explain the Connection Between Borderline Personality Disorder Features and Number of Sexual Partners? ( 28072043 )
2017
29
Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. ( 28086181 )
2017
30
Seven-Year Course of Borderline Personality Disorder Features: Borderline Pathology Is as Unstable as Depression during Adolescence. ( 28920008 )
2017
31
Narrative self-appropriation: embodiment, alienness, and personal responsibility in the context of borderline personality disorder. ( 28895019 )
2017
32
The overlap between autistic spectrum conditions and borderline personality disorder. ( 28886113 )
2017
33
The specificity of emotion dysregulation in adolescents with borderline personality disorder: comparison with psychiatric and healthy controls. ( 28078089 )
2017
34
Altered Empathy for Psychological and Physical Pain in Borderline Personality Disorder. ( 28072040 )
2017
35
Creativity and borderline personality disorder: evidence from a voxel-based morphometry study. ( 27174566 )
2016
36
Health care costs of borderline personality disorder and matched controls with major depressive disorder: a comparative study based on anonymized claims data. ( 27990594 )
2016
37
Borderline Personality Disorder in the Emergency Department: Good Psychiatric Management. ( 27603743 )
2016
38
Association between schizotypal and borderline personality disorder traits, and cannabis use in young adults. ( 27149691 )
2016
39
The Emergence of a Generalist Model to Meet Public Health Needs for Patients With Borderline Personality Disorder. ( 27133405 )
2016
40
Hyper-modulation of brain networks by the amygdala among women with Borderline Personality Disorder: Network signatures of affective interference during cognitive processing. ( 28086129 )
2016
41
Prevalence of Borderline Personality Disorder in University Samples: Systematic Review, Meta-Analysis and Meta-Regression. ( 27171206 )
2016
42
Abnormal white matter structural connectivity in treatment-naA^ve young adults with borderline personality disorder. ( 27611589 )
2016
43
Interpersonal emotion regulation in Asperger's syndrome and borderline personality disorder. ( 27990657 )
2016
44
A new intervention for people with borderline personality disorder who are also parents: a pilot study of clinician acceptability. ( 27617096 )
2016
45
The Main and Interactive Effects of Maternal Interpersonal Emotion Regulation and Negative Affect on Adolescent Girls' Borderline Personality Disorder Symptoms. ( 27185969 )
2016
46
Cognitive and affective processing of social exclusion in borderline personality disorder and social anxiety disorder. ( 27616717 )
2016
47
The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. ( 27107850 )
2016
48
"Good Enough" Psychiatric Residency Training in Borderline Personality Disorder: Challenges, Choice Points, and a Model Generalist Curriculum. ( 27603744 )
2016
49
Preliminary Evidence for Emotion Dysregulation as a Mechanism Underlying Poor Sleep Quality in Borderline Personality Disorder. ( 27617649 )
2016
50
Biting the hand that feeds: current opinion on the interpersonal causes, correlates, and consequences of borderline personality disorder. ( 27990277 )
2016

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.97 BDNF HTR1A HTR1B
2
Show member pathways
11.92 AVPR1A HTR2A HTR2C
3 11.91 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
4
Show member pathways
11.68 HTR1A HTR1B HTR2A HTR2C
5 11.55 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
6
Show member pathways
10.98 COMT MAOA SLC6A4
7
Show member pathways
10.78 COMT MAOA TPH1
8 10.76 HTR2A HTR2C
9 10.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
10 10.58 COMT MAOA
11
Show member pathways
10.55 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.17 AVPR1A HTR1A HTR1B HTR2A HTR2C NRXN3

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.83 HTR1B HTR2A HTR2C NRXN3
2 response to drug GO:0042493 9.77 COMT HTR1B HTR2A HTR2C SLC6A4
3 positive regulation of fat cell differentiation GO:0045600 9.65 HTR2A HTR2C TPH1
4 social behavior GO:0035176 9.63 AVPR1A NRXN3 SLC6A4
5 release of sequestered calcium ion into cytosol GO:0051209 9.62 HTR2A HTR2C
6 positive regulation of vasoconstriction GO:0045907 9.61 AVPR1A HTR2A
7 behavioral fear response GO:0001662 9.61 HTR1A HTR2C
8 activation of phospholipase C activity GO:0007202 9.6 AVPR1A HTR2A
9 regulation of dopamine secretion GO:0014059 9.59 HTR1B HTR2A
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.58 HTR1B HTR2A
11 bone remodeling GO:0046849 9.57 HTR1B TPH1
12 neurotransmitter catabolic process GO:0042135 9.56 COMT MAOA
13 catecholamine metabolic process GO:0006584 9.55 COMT MAOA
14 dopamine catabolic process GO:0042420 9.54 COMT MAOA
15 sperm ejaculation GO:0042713 9.51 AVPR1A SLC6A4
16 regulation of hormone secretion GO:0046883 9.49 HTR1A HTR2A
17 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.43 HTR1A HTR1B
18 vasoconstriction GO:0042310 9.43 HTR1A HTR1B SLC6A4
19 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.4 HTR2A HTR2C
20 regulation of behavior GO:0050795 9.33 HTR1A HTR1B HTR2A
21 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.32 HTR2A HTR2C
22 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR2C
23 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C
24 signal transduction GO:0007165 10.13 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
25 G-protein coupled receptor signaling pathway GO:0007186 10.02 AVPR1A HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.8 AVPR1A HTR1A HTR1B HTR2A HTR2C
2 signal transducer activity GO:0004871 9.72 AVPR1A HTR1A HTR1B HTR2A HTR2C
3 drug binding GO:0008144 9.54 HTR1B HTR2A HTR2C
4 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
6 G-protein coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
7 serotonin binding GO:0051378 8.92 HTR1A HTR1B HTR2A HTR2C

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....